Literature DB >> 17468157

Overview of the changing paradigm in cancer treatment: oral chemotherapy.

Joseph Aisner1.   

Abstract

PURPOSE: Several new oral chemotherapeutic agents have recently been introduced. Many possess novel mechanisms of action and specific targets that result in different adverse effect profiles from those associated with traditional chemotherapies and hormonal therapies. The potential advantages and challenges associated with oral chemotherapy are discussed.
SUMMARY: Use of the oral route is convenient and allows administration to take place at home or in non-traditional settings. However, nausea, difficulty swallowing, patient nonadherence, interactions with drugs and food, other pharmacokinetic factors, and the high cost of treatment can present problems in using these agents by the oral route. Awareness by clinicians of the potential problems with oral chemotherapy can help to avoid or minimize problems that might affect patient outcomes.
CONCLUSION: While bioavailability studies are often an integral part of developing oral agents, their comparisons with parenteral forms are less well documented. However, studies comparing intravenous 5-fluorouracil (5-FU) with oral 5-FU prodrugs have demonstrated that efficacy, safety, and quality of life are not compromised by the use of oral therapy. Finally, these studies, as well as others, reveal patients prefer the oral route of administration.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17468157     DOI: 10.2146/ajhp070035

Source DB:  PubMed          Journal:  Am J Health Syst Pharm        ISSN: 1079-2082            Impact factor:   2.637


  32 in total

1.  Synthesis and biological evaluation of 2-amino-1-thiazolyl imidazoles as orally active anticancer agents.

Authors:  Wen-Tai Li; Der-Ren Hwang; Jen-Shin Song; Ching-Ping Chen; Tung-Wei Chen; Chi-Hung Lin; Jiunn-Jye Chuu; Tzu-Wen Lien; Tsu-An Hsu; Chen-Lung Huang; Huan-Yi Tseng; Chu-Chung Lin; Heng-Liang Lin; Chung-Ming Chang; Yu-Sheng Chao; Chiung-Tong Chen
Journal:  Invest New Drugs       Date:  2010-10-02       Impact factor: 3.850

2.  Patient and provider perspectives on delivery of oral cancer therapies.

Authors:  Caitlin C Murphy; Simon J Craddock Lee; David E Gerber; John V Cox; Hannah M Fullington; Robin T Higashi
Journal:  Patient Educ Couns       Date:  2019-06-20

3.  Survey of oral chemotherapy safety and adherence practices of hospitals in Spain.

Authors:  David Conde-Estévez; Esther Salas; Joan Albanell
Journal:  Int J Clin Pharm       Date:  2013-10-16

4.  Inpatient and outpatient pharmacy monitoring of oral antineoplastic medications.

Authors:  Ross Jason Bindler
Journal:  Hosp Pharm       Date:  2015-02

5.  Multidisciplinary Optimization of Oral Chemotherapy Delivery at the University of Wisconsin Carbone Cancer Center.

Authors:  Daniel L Mulkerin; Jason J Bergsbaken; Jessica A Fischer; Mary J Mulkerin; Aaron M Bohler; Mary S Mably
Journal:  J Oncol Pract       Date:  2016-10       Impact factor: 3.840

6.  Pharmaceutical care program for onco-hematologic outpatients: safety, efficiency and patient satisfaction.

Authors:  Almudena Ribed; Rosa María Romero-Jiménez; Vicente Escudero-Vilaplana; Irene Iglesias-Peinado; Ana Herranz-Alonso; Carlos Codina; Maria Sanjurjo-Sáez
Journal:  Int J Clin Pharm       Date:  2015-12-29

7.  Cancer drug expenditure in British Columbia and Saskatchewan: a trend analysis.

Authors:  Reka Pataky; David A Tran; Andrea Coronado; Riaz Alvi; Darryl Boehm; Dean A Regier; Stuart Peacock
Journal:  CMAJ Open       Date:  2018-07-27

8.  Safe handling of oral chemotherapeutic agents in clinical practice: recommendations from an international pharmacy panel.

Authors:  Susan Goodin; Niesha Griffith; Beth Chen; Karen Chuk; Mikael Daouphars; Christian Doreau; Rinku A Patel; Rowena Schwartz; Maria José Tamés; Robert Terkola; Barbara Vadnais; Debbie Wright; Klaus Meier
Journal:  J Oncol Pract       Date:  2011-01       Impact factor: 3.840

9.  Identification of risks associated with the prescribing and dispensing of oral anticancer medicines in Ireland.

Authors:  Lisa Hammond; Elaine Marsden; Niamh O'Hanlon; Fionnuala King; Martin Charles Henman; Claire Keane
Journal:  Int J Clin Pharm       Date:  2012-09-09

10.  Improving the Safety of Oral Chemotherapy at an Academic Medical Center.

Authors:  Nirav N Shah; Erica Casella; Donna Capozzi; Suzanne McGettigan; Tara C Gangadhar; Lynn Schuchter; Jennifer S Myers
Journal:  J Oncol Pract       Date:  2016-01-05       Impact factor: 3.840

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.